Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights
Rheumatology & Autoimmunity · 2026-06 · 6 (2) · 71-82
DOI: 10.1002/rai2.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology & Autoimmunity, online erschienen am 18.12.2025. Verfasst von Yingjia Chen und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Municipal Natural Science Foundation.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease primarily characterized by erosive arthritis. It can lead to joint pain, swelling, and deformity, significantly affecting patients' quality of life. RA results from the interaction of multiple factors, including genetic, environmental, and immune components, and its pathogenesis has not yet been fully elucidated. Existing treatment regimens have several limitations. Mesenchymal stromal cell (MSC) therapy has shown promising therapeutic potential in both preclinical and clinical studies due to its unique biological properties, such as multi‐lineage differentiation potential, immunomodulatory functions, low immunogenicity, and strong tissue repair capacity. This article provides a comprehensive review of the long‐term efficacy, safety, and potential mechanisms underlying MSC therapy for RA, with the aim of proposing MSC‐based strategies to optimize therapeutic outcomes.
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Natural Science Foundation
Zitieren
APA
Chen, Y., Gao, R., Guo, X., Yao, G., Tang, X., Liu, Y. E., & Sun, L. (2026). Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights. Rheumatology & Autoimmunity, 6(2), 71-82. https://doi.org/10.1002/rai2.70032
Vancouver
Chen Y, Gao R, Guo X, Yao G, Tang X, Liu YE, et al. Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights. Rheumatology & Autoimmunity. 2026;6(2):71-82. doi:10.1002/rai2.70032
BibTeX
@article{Chen2026,
author = {Chen, Yingjia and Gao, Ruiyu and Guo, Xing and Yao, Genhong and Tang, Xiaojun and Liu, Yile E. and Sun, Lingyun},
title = {Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights},
journal = {Rheumatology & Autoimmunity},
year = {2026},
volume = {6},
number = {2},
pages = {71--82},
doi = {10.1002/rai2.70032}
}
EUVIMED